Drug Trial Radar · NCT06245915
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
37
Actual
Start
Feb 26, 2024
Primary completion
Dec 31, 2026
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Arsenal Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label phase 1/2 trial evaluating the safety and efficacy of AB-2100 cell product. The study may enroll approximately 60 patients in phase 1 and approximately 70 patients in phase 2.
Conditions
- Advanced/Metastatic Clear Cell Renal Cell Carcinoma
- Recurrence
Interventions
AB-2100Biological
autologous T cell therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 (Dose escalation): incidence of adverse eventsTime frame: From AB-2100 infusion up to 21 days post infusion
- Phase 2 (Cohort expansion): Objective response rate (ORR)Time frame: From AB-2100 infusion up to 24 months post-infusion
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
City of Hope
Duarte, California
Moffitt Cancer Center
Tampa, Florida
University of Iowa and Holden Comprehensive Cancer Center
Iowa City, Iowa
Dana Farber Cancer Institue
Boston, Massachusetts
Perlmutter Cancer Center - NYU Langone Health
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
MD Anderson Cancer Center
Houston, Texas
Huntsman Cancer Institute - Univ of Utah Health
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.